Amgen: Positive results from osteoporosis drug study

[MoneyGuy]

SAN FRANCISCO (MarketWatch) -- Amgen said late Friday that a Phase 3 study where patients received denosumab, a RANK Ligand inhibitor, demonstrated a significant reduction in the incidence of new vertebral fractures compared with placebo treatment. Women receiving denosumab also experienced a significant decline in the incidence of new non-vertebral and hip fractures. At the same time, the incidence and types of adverse events, including serious infections and neoplasms, were similar between the denosumab and placebo groups, Amgen said. The three-year international study involved 7,800 women with osteoporosis.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

http://feeds.marketwatch.com/~a/marketwatch/marketpulse?i=xbZYrb (http://feeds.marketwatch.com/~a/marketwatch/marketpulse?a=xbZYrb)

http://feeds.marketwatch.com/~f/marketwatch/marketpulse?i=UNrBIJ (http://feeds.marketwatch.com/~f/marketwatch/marketpulse?a=UNrBIJ) http://feeds.marketwatch.com/~f/marketwatch/marketpulse?i=xa5nyj (http://feeds.marketwatch.com/~f/marketwatch/marketpulse?a=xa5nyj) http://feeds.marketwatch.com/~f/marketwatch/marketpulse?i=PXtuqj (http://feeds.marketwatch.com/~f/marketwatch/marketpulse?a=PXtuqj) http://feeds.marketwatch.com/~f/marketwatch/marketpulse?i=M38KvJ (http://feeds.marketwatch.com/~f/marketwatch/marketpulse?a=M38KvJ)
http://feeds.marketwatch.com/~r/marketwatch/marketpulse/~4/346025431

More... (http://feeds.marketwatch.com/~r/marketwatch/marketpulse/~3/346025431/story.aspx)